Does Edwards Lifesciences (EW) Have Strong Double-Digit Earnings Potential?

2 weeks ago 14

Soumya Eswaran

Mon, January 19, 2026 astatine 8:25 AM CST 3 min read

Wedgewood Partners, an concern absorption company, released its fourth-quarter 2025 capitalist letter. The steadfast anticipates stronger marketplace volatility successful the coming years and has moderated its enthusiasm. A transcript of the missive tin beryllium downloaded here. The Wedgewood Composite returned -1.8% (net) successful the 4th fourth compared to the S&P 500’s 2.7%, the Russell 1000 Growth Index’s 1.1%, and the Russell 1000 Value Index’s 3.8% returns. YTD, the Composite gained 4.3% compared to 17.9%, 18.6%, and 15.9% returns for the indexes, respectively. Wedgewood Partners’ absorption connected high-quality stocks has historically worked since 1992, but not successful 2025. The missive highlighted mediocre banal selection, the portfolio’s beardown past performers owed for valuation correction, and being structurally underweight successful AI stocks drove the underperformance. The missive noted that successful 2026, crowded AI investments and stretched valuations make unit connected prudent concern decisions. In addition, you tin cheque the Fund’s apical 5 holdings to find its champion picks for 2025.

In its fourth-quarter 2025 capitalist letter, Wedgewood Partners highlighted stocks specified arsenic Edwards Lifesciences Corporation (NYSE:EW). Edwards Lifesciences Corporation (NYSE:EW) offers products and technologies for structural bosom illness and captious attraction monitoring. On January 16, 2026, Edwards Lifesciences Corporation (NYSE:EW) banal closed astatine $84.35 per share. One-month instrumentality of Edwards Lifesciences Corporation (NYSE:EW) was -2.52%, and its shares gained 20.88% of their worth implicit the past 52 weeksEdwards Lifesciences Corporation (NYSE:EW) has a marketplace capitalization of $49.522 billion.

Wedgewood Partners stated the pursuing regarding Edwards Lifesciences Corporation (NYSE:EW) successful its 4th fourth 2025 capitalist letter:

"Edwards Lifesciences Corporation (NYSE:EW) besides contributed to show during the quarter. The Company presented favorable seven-year information for its transcatheter aortic valves, whereas competitory valves person exited respective cardinal markets. Edwards tin thrust double-digit net maturation implicit the adjacent fewer years, arsenic its semipermanent information serves to germinate the standards of attraction and volition marque it easier for patients, doctors, and wellness systems to opt for its minimally invasive alternatives versus unfastened bosom surgery."

Jim Cramer Notes Edwards Lifesciences (EW) is successful a “Good Zone”

Edwards Lifesciences Corporation (NYSE:EW) is not connected our database of 30 Most Popular Stocks Among Hedge Funds. According to our database, 64 hedge money portfolios held Edwards Lifesciences Corporation (NYSE:EW) astatine the extremity of the 3rd quarter, compared to 65 successful the erstwhile quarter. While we admit the imaginable of Edwards Lifesciences Corporation (NYSE:EW) arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.